InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1 |
VJZITPJGSQKZMX-XDPRQOKASA-N |
O([C@H]1C[C@H](O)[C@@H](CO1)O)[C@@H]2C=3C(=C(O)C4=C(C3O)C(=O)C=5C(C4=O)=CC=CC5)C[C@](C2)(C(C)=O)N |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
topoisomerase II inhibitor
A topoisomerase inhibitor that inhibits DNA topoisomerase II.
antimicrobial agent
A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
(via anthracycline antibiotic )
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via anthracycline )
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
prodrug
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
|
|
View more via ChEBI Ontology
(1S,3S)-3-acetyl-3-amino-5,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2-deoxy-β-D-erythro-pentopyranoside
|
amrubicin
|
ChEBI
|
amrubicina
|
ChEBI
|
amrubicine
|
ChEBI
|
amrubicinum
|
ChEBI
|
(7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxytetrahydro-2H-pyran-2-yl]oxy}-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
|
IUPAC
|
SM-5887
|
ChEBI
|
110267-81-7
|
CAS Registry Number
|
ChemIDplus
|
110267-81-7
|
CAS Registry Number
|
DrugCentral
|
31505087
|
PubMed citation
|
Europe PMC
|
31557562
|
PubMed citation
|
Europe PMC
|
31901017
|
PubMed citation
|
Europe PMC
|
32462731
|
PubMed citation
|
Europe PMC
|
32569168
|
PubMed citation
|
Europe PMC
|
32582522
|
PubMed citation
|
Europe PMC
|
32606979
|
PubMed citation
|
Europe PMC
|
9849587
|
PubMed citation
|
Europe PMC
|
|